share_log

VBI Vaccines Secures $100M Debt Facility From K2 HealthVentures

VBI Vaccines Secures $100M Debt Facility From K2 HealthVentures

VBI疫苗公司從K2 HealthVentures獲得1億美元的債務融資
Benzinga Real-time News ·  2022/09/15 08:32
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
VBI VBI Vaccines Inc.(納斯達克股票代碼:VBIV)(VBI)是一家由免疫學推動的生物製藥公司,致力於強有力的疾病預防和治療。該公司今天宣佈,它已與現有貸款人K2 HealthVentures(K2HV)簽訂了一項高達1億美元的再融資和升級債務安排,K2 HealthVentures是一家專注於醫療保健的專業金融公司。
Under the terms of the agreement, $50 million is immediately available to VBI upon closing, comprised of $30 million to refinance the outstanding facility the Company held with K2HV, and an incremental $20 million of non-dilutive funding. Future tranches of up to $25 million are committed and will be made available to VBI upon the...
根據協議條款,VBI在完成交易後可立即獲得5,000萬美元,其中包括3,000萬美元用於對公司與K2H...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論